Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its ...

This was the stock's second consecutive day of gains.

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler presentations and more severe and prolonged lesions compared to patients with ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

The Allspring Large Cap Core Fund generated a total return of -5.78% for the quarter vs. the benchmark S&P 500 Index's -4.27% ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Offers In-Person and Virtual Access to Education, Support, and Community Eos Connection is more than a confere ...